Pirfenidone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Pirfenidone: From Idiopathic Pulmonary Fibrosis to Extracutaneous Mastocytoma
One-Sentence Summary
Pirfenidone is an oral antifibrotic agent established for the treatment of idiopathic pulmonary fibrosis (IPF), acting through inhibition of TGF-β1- and PDGF-mediated fibroblast proliferation and collagen synthesis. The TxGNN model predicts it may be effective for Extracutaneous Mastocytoma, with a prediction score of 99.71%, but currently no clinical trials and no publications support this specific direction — the prediction is model-derived only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Idiopathic Pulmonary Fibrosis (IPF) — not recorded in the evidence pack; inferred from established drug identity |
| Predicted New Indication | Extracutaneous Mastocytoma |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for pirfenidone is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on information surfaced elsewhere in this pack (literature cited under a separate predicted indication), pirfenidone is known to inhibit TGF-β1, PDGF, EGF and FGF signaling, thereby reducing fibroblast proliferation and collagen deposition — the mechanism underlying its approved use in IPF.
Extracutaneous mastocytoma is a rare neoplastic proliferation of mast cells driven primarily by KIT mutations, a pathway mechanistically unrelated to TGF-β-driven fibrosis. The repurposing rationale attached to this prediction explicitly notes that the high TxGNN score likely reflects a shared "fibrosis/stromal remodeling" graph neighborhood rather than a genuine mechanistic connection, and states there is no direct link between anti-TGF-β activity and KIT-driven mast cell pathology.
Given the absence of any preclinical, clinical trial, or literature support, this prediction should be interpreted as a graph-similarity signal rather than a mechanistically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Pirfenidone is not currently marketed in Norway (0 authorizations on record). No license or product information is available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but it is unsupported by any clinical trial, real-world, or literature evidence (Evidence Level L5), and the proposed mechanistic link between anti-fibrotic TGF-β inhibition and KIT-driven mast cell pathology is not established. TFDA/label-level safety data (warnings, contraindications) is also missing (Blocking data gap DG001), which independently prevents any safety pre-assessment.
To proceed, the following is needed:
- TFDA-equivalent product labeling — warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action data for pirfenidone (DG002, High)
- Preclinical evidence directly linking anti-fibrotic activity to mast cell tumor biology
- Note: a separate candidate in this pack, fibroblastic neoplasm (rank 9, Evidence Level L4/S1), has meaningfully more support (6 publications, including a pilot cohort on desmoid tumors) but also carries a safety red flag — two case reports of sarcoma progression and dermatofibroma aggravation following pirfenidone use. This candidate warrants separate causality review and may be a more actionable priority than the current top-ranked prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.